PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION

Abstract

Pharmacoeconomic evaluation of treatment of the second and third lines of multiple myeloma with Revlimid in Russia was conducted. It has shown, that application of lenalidomide as a drug of choice in the treatment of multiple myeloma in second-line therapy and is preferable from the perspective of the health economics.

Keywords

• multiple myeloma
• of cost-effectiveness analysis lenalidomide
• revlimid
• bortezomib
• velcade
• pharmacoeconomics